BridgeBio Pharma enters September with the options panic from last week fully unwound, yet the underlying short position is quietly growing again — a tension worth watching as the stock slides toward its next earnings date in late October.
The options story has reversed sharply since the previous note flagged an unusual PCR spike. That put/call ratio has collapsed from its August 25 peak back to 0.16, well below its 20-day average of 0.18 — now sitting near the low end of the past year's range. Options traders who were scrambling for downside protection a week ago have largely abandoned that hedge. The z-score of -1.4 confirms the current reading is the least defensive it has been in months. Whatever drove that single-session spike appears to have been transient rather than structural.
Short interest tells a more persistent story, though. The position has climbed roughly 2.6% over the past week to 12.1% of free float — about 23.4 million shares — and is now back to levels consistent with early August before a sharper reduction. Month-on-month the position is actually down nearly 10%, reflecting that a genuine unwind happened in mid-August. But the direction has since reversed: shorts added around 700,000 shares over the last five sessions. Crucially, the borrow market offers no friction to this rebuilding. Availability is extraordinarily loose at roughly 1,470% — meaning lenders hold nearly fifteen times as many shares available as are currently shorted. Cost to borrow is just 0.48%, essentially free money for anyone wanting to build a new short. Those conditions make it trivially easy to add pressure.
The Street, by contrast, is about as constructive as it gets. Mizuho raised its target from $96 to $110 on September 1, and JPMorgan moved theirs from $100 to $111 in mid-August. Only Morgan Stanley trimmed slightly, from $98 to $97, while keeping its Overweight rating. The mean analyst target runs around $109 — roughly 42% above the current price of $76.57 — and every recent change except that one trim was an upgrade or a raise. Factor scores back the bull case selectively: EPS momentum over 30 days ranks in the 95th percentile and forward EPS growth ranks 86th. The bear case centres on the debt load and the binary nature of pipeline execution, both of which the short interest level reflects.
Two names on the 13D register complicate the ownership picture. Viking Global Investors filed an amended Schedule 13D in July showing a reduction from 6.1% to 5.0%, and KKR Group Partnership filed similarly in August, cutting from 7.0% to 4.7%. Both are on 13D filings — meaning activist or strategic intent was originally declared — and both have trimmed materially. Vanguard, notable for previously holding an 8.68% stake, disclosed it had exited entirely as of March. These aren't distressed exits, but the pattern of large sophisticated holders reducing at current prices is a data point the Street's bullish targets don't fully account for. Stakes are as-last-disclosed and any holder dropping below 5% may not file again.
The stock fell 4.8% on the week to $76.57, broadly in line with peers: DYN was off 4.7% and ROIV dropped 5.3%, suggesting sector-wide softness rather than BBIO-specific selling. SYRE and FHTX fared far worse, down 17.6% and 16.9% respectively. With Q3 results due October 30, the next month is less about whether the analyst consensus is right on valuation and more about whether the pipeline newsflow between now and then gives shorts any reason to add conviction or bulls any catalyst to re-engage.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
